Mathieu Grangeon1, Pascale Tomasini2, Solene Chaleat1, Arnaud Jeanson1, Maxime Souquet-Bressand1, Nataliya Khobta3, Julien Bermudez1, Youssef Trigui1, Laurent Greillier4, Marilyne Blanchon1, Mohamed Boucekine5, Celine Mascaux4, Fabrice Barlesi4. 1. Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France. 2. Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Aix Marseille University, Inserm U911 CRO2, Marseille, France. Electronic address: pascale.tomasini@ap-hm.fr. 3. Oncology Department, Centre Hospitalier Departemental de Castellccio, Ajaccio, France. 4. Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Aix Marseille University, Inserm U911 CRO2, Marseille, France. 5. Chronic Diseases and Quality of Life -Research Unit, Aix Marseille University, EA 3279 - Public Health, Marseille, France.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non-small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs). The incidence, diagnosis, and treatment of IRAEs are quite acknowledged; however, the link between IRAEs and the efficacy of ICIs requires further clarification. The objectives of this study were to assess the association between IRAEs incidence and severity and ICIs efficacy in patients with advanced NSCLC. METHODS: In this retrospective study, clinical, biological, treatment, and outcome data were collected from patients with advanced NSCLC who received at least 1 cycle of ICIs from April 2013 to February 2017. The primary endpoint was to assess the association of IRAEs incidence with overall survival (OS). Secondary endpoints were the association of IRAEs with progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). RESULTS: Overall, 270 patients were studied. The median OS was 14 months, median PFS was 2.6 months, ORR was 13%, and DCR was 51%. OS, PFS, and ORR were significantly better for patients with IRAEs compared with patients with no IRAEs, translating to median OS not reached versus 8.21 months, respectively (hazard ratio, 0.29; 95% confidence interval [CI], 0.18-0.46; P < .001); PFS was 5.2 versus 1.97 months (hazard ratio, 0.42; 95% CI, 0.32-0.57; P < .001); and ORR was 212.9% versus 5.7% (odds ratio, 4.9; 95% CI, 2.18-11.05; P < .001). CONCLUSIONS: This report presents the largest case series showing longer OS and PFS and better ORR when IRAEs occurred in a population of patients with advanced NSCLC treated with ICIs. The biological background for this phenomenon is being explored prospectively.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non-small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs). The incidence, diagnosis, and treatment of IRAEs are quite acknowledged; however, the link between IRAEs and the efficacy of ICIs requires further clarification. The objectives of this study were to assess the association between IRAEs incidence and severity and ICIs efficacy in patients with advanced NSCLC. METHODS: In this retrospective study, clinical, biological, treatment, and outcome data were collected from patients with advanced NSCLC who received at least 1 cycle of ICIs from April 2013 to February 2017. The primary endpoint was to assess the association of IRAEs incidence with overall survival (OS). Secondary endpoints were the association of IRAEs with progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). RESULTS: Overall, 270 patients were studied. The median OS was 14 months, median PFS was 2.6 months, ORR was 13%, and DCR was 51%. OS, PFS, and ORR were significantly better for patients with IRAEs compared with patients with no IRAEs, translating to median OS not reached versus 8.21 months, respectively (hazard ratio, 0.29; 95% confidence interval [CI], 0.18-0.46; P < .001); PFS was 5.2 versus 1.97 months (hazard ratio, 0.42; 95% CI, 0.32-0.57; P < .001); and ORR was 212.9% versus 5.7% (odds ratio, 4.9; 95% CI, 2.18-11.05; P < .001). CONCLUSIONS: This report presents the largest case series showing longer OS and PFS and better ORR when IRAEs occurred in a population of patients with advanced NSCLC treated with ICIs. The biological background for this phenomenon is being explored prospectively.
Authors: Kennedy Yao Yi Ng; Sze Huey Tan; Jack Jie En Tan; Desiree Shu Hui Tay; Ailica Wan Xin Lee; Andrea Jing Shi Ang; Lawrence Wen Jun Wong; Su Pin Choo; David Wai-Meng Tai; Joycelyn Jie Xin Lee Journal: Liver Cancer Date: 2021-10-26 Impact factor: 11.740
Authors: Mario Giovanni Chilelli; Carlo Signorelli; Julio Rodrigo Giron Berrios; Angelo Onorato; Fabrizio Nelli; Maria Agnese Fabbri; Francesca Primi; Eleonora Marrucci; Antonella Virtuoso; Marta Schirripa; Marco Mazzotta; Enzo Maria Ruggeri Journal: Cancer Diagn Progn Date: 2022-01-03
Authors: Satya Das; Kristen K Ciombor; Sigurdis Haraldsdottir; Yoanna Pumpalova; Ibrahim H Sahin; G Pineda; Yu Shyr; E P Lin; Chih-Yuan Hsu; Shih-Kai Chu; Laura W Goff; Dana B Cardin; Mehmet A Bilen; George A Fisher; Christina Wu; Jordan Berlin Journal: Oncologist Date: 2020-01-14
Authors: Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2020-05-23 Impact factor: 11.527